14 May 2021 - New drug application, submitted in March, is for locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication
Astellas today announced Japan's Ministry of Health, Labour and Welfare (MHLW) has granted priority review for the company’s new drug application, which was submitted in March.
If approved, enfortumab vedotin would be the first antibody drug conjugate available in Japan for the treatment of patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication.